Efficacy and clinical monitoring strategies for immune checkpoint inhibitors and targeted cytokine immunotherapy for locally advanced and metastatic colorectal cancer

•“Bench to bedside” perspective of current pre-clinical/clinical trials and FDA-approved drugs to treat metastatic/locally advanced CRC.•Discussing “bench to bedside” perspective of current pre-clinical and clinical trials, along with current FDAapproved drugs that fall under cytokine inhibitors to...

Full description

Saved in:
Bibliographic Details
Published inCytokine & growth factor reviews Vol. 49; pp. 1 - 9
Main Authors Bess, Shelby N., Greening, Gage J., Muldoon, Timothy J.
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.10.2019
Subjects
Checkpoint
Clinical
Colorectal cancer
Cytokine
Immunotherapy
Inhibition
Clinical
Checkpoint
Inhibition
Immunotherapy
Colorectal cancer
Cytokine
Online AccessGet full text

Cover

More Information
Summary:•“Bench to bedside” perspective of current pre-clinical/clinical trials and FDA-approved drugs to treat metastatic/locally advanced CRC.•Discussing “bench to bedside” perspective of current pre-clinical and clinical trials, along with current FDAapproved drugs that fall under cytokine inhibitors to treat metastatic and locally advanced colorectal cancer.•“Bench to beside” perspective of emerging technologies used to monitor treatment response in patients with metastatic/locally advanced CRC. Colorectal cancer (CRC) is the fourth most common cancer type and is the second leading cause of cancer deaths annually in the United States. Conventional treatment options include postoperative (adjuvant) and preoperative (neoadjuvant) chemotherapy and radiotherapy. Although these treatment modalities have shown to decrease tumor burden, a major limitation to chemothearpy/radiotherapy is the high recurrence rate in patients. Immune-modulation strategies have emerged as a promising new therapeutic avenue to reduce this recurrence rate while minimizing undesirable systemic side effects. This review will focus specifically on the mechanisms of monoclonal antibodies: immune checkpoint inhibitors and cytokines, as well as current drugs approved by the Food and Drug Administration (FDA) and new clinical/pre-clinical trials. Finally, this review will investigate emerging methods used to monitor tumor response post-treatment.
ISSN:1359-6101
1879-0305
DOI:10.1016/j.cytogfr.2019.10.002